Midwest Business Group on Health’s Post

Amidst corporate maneuvers, the Labcorp acquisition of Tufts Medicine's outreach lab extends diagnostic reach as a whole. This move prompts a reflection on the intricate balance between expansion and its broader impact, urging a blend of growth with ethical considerations. Looking ahead, Labcorp's deal with Tufts reflects healthcare's evolution in a market-driven world. These alliances are becoming the norm, streamlining services while disrupting employment. Balancing efficiency and empathy poses a challenge, requiring models that fuse growth with societal welfare. The future necessitates innovative approaches that prioritize community and individual well-being, not just financial gain. #Labcorp #Tufts #TuftsMedicine #Healthcare

Top 5 posters I saw today at #ASCO2024. #3… Remote oncology pharmacists can improve quality of care and save provider time. Innovative way to improve utilization of scarce clinical resources and maybe reduce burnout…very exciting

Digital therapeutics (DTx) offer an opportunity for improved mental health care following years of the sector being traditionally neglected by new therapy development. The current fragmentation of the mental health care sector in the US is partly due to the severe shortage of mental health professionals as well as the growth in demand after a spike during the COVID-19 pandemic. DTx and its subcategory, prescription digital therapeutics (PDTs), can serve as an extension or parallel option to conventional care. PDTs can alleviate some traditional barriers to care access due to the avoidance of stigma and the overcoming of geographic barriers. As more products start to demonstrate safety and efficacy, the market for DTx will expand – predicted to reach $56 billion by 2025. Read more about the landscape for DTx and PDTs in our new article by Katie Hayes at https://buff.ly/3PeG3p3 #DigitalTherapeutics #DTX #PDT #MentalHealth #MarketAccess

Though provoking article on the growing use and potential for Digital therapeutics in mental health care delivery. Following the COVID pandemic use of these services grew strongly. In all established health economies growth in this new sector is expected. Take a read and let me know your thoughts. #DigitalTherapeutics #DTX #PDT #MentalHealth #MarketAccess

🔆 The Dawn of Personalized Medicine: Clinical Pharmacists at the Vanguard of #Pharmacogenomics 📌 Today, I had the privilege of attending a compelling presentation by Associate Professor Maria Pashayan , whose insights into pharmacogenomics (PGx) have inspired me to delve deeper into this #transformative #field. 🚀 Her expertise and the #valuable #information she shared have reinforced my belief in the power of PGx to reshape #chronic #disease management. ✅️ As a #clinicalpharmacist, I am witnessing a paradigm shift in #patient #care, thanks to PGx. This innovative approach considers each patient's #genetic makeup, enabling us to customize #treatments for chronic ailments such as #diabetes, #heartdisease, and #cancer with unprecedented precision. 🟢 Here's a glimpse of how PGx is #revolutionizing #healthcare: ♦️Precision in #medication #selection: We're now equipped to choose the most effective drugs for our patients based on their genetic profiles. ♦️Proactive #sideeffect management: By identifying patients predisposed to adverse drug reactions, we can prevent detrimental effects before they occur. ♦️Tailored medication #dosages: Determining the ideal dosage for each patient has become more accurate, ensuring optimal treatment efficacy. ♦️ #Economical healthcare delivery: PGx aids in reducing unnecessary healthcare expenditures by avoiding ineffective treatments and #adverseevents. 🚩 Looking ahead, PGx's role in #immunotherapy heralds a new era of cancer treatment, characterized by personalized care and reduced side effects. 🎯 The integration of cutting-edge technologies like single-cell analysis and hiPSCs is accelerating the progress in this domain, promising better outcomes for cancer patients. ✍️ In the realm of #clinicalpharmacy, our expertise is crucial for incorporating PGx into everyday healthcare practices. Our deep understanding of medication therapy management, combined with the #insights provided by PGx, empowers us to enhance drug therapy and patient care significantly. ✳️ I extend my #heartfelt thanks to Associate Professor Pashayan for her enlightening presentation. It's an exciting time to be part of the healthcare community, and I am eager to contribute to the ongoing #evolution of chronic disease management through pharmacogenomics. #Pharmacogenomics #ClinicalPharmacy #ChronicDiseaseManagement #PersonalizedMedicine #HealthcareInnovation

Digital therapeutics (DTx) offer an opportunity for improved mental health care following years of the sector being traditionally neglected by new therapy development. The current fragmentation of the mental health care sector in the US is partly due to the severe shortage of mental health professionals as well as the growth in demand after a spike during the COVID-19 pandemic. DTx and its subcategory, prescription digital therapeutics (PDTs), can serve as an extension or parallel option to conventional care. PDTs can alleviate some traditional barriers to care access due to the avoidance of stigma and the overcoming of geographic barriers. As more products start to demonstrate safety and efficacy, the market for DTx will expand – predicted to reach $56 billion by 2025. Read more about the landscape for DTx and PDTs in our new article by Katie Hayes at https://buff.ly/3KUqmAY #DigitalTherapeutics #DTX #PDT #MentalHealth #MarketAccess

Despite comprising over half the world's population, women made up only 34% of Phase 1 clinical trial participants for FDA-approved drugs between 2013-2015. In a recent Clinical Leader article, Juan Camilo Arjona Ferreira, Organon's Chief Medical Officer & Head of R&D, highlights the enduring gender biases in drug development and explores opportunities to address current data gaps. The limited involvement of women in clinical trials contributes to expanding knowledge disparities, ultimately affecting health outcomes. The road to health equity is long, but the momentum is building. Join us and others in #womenshealth to make 2024 the year of transformation. 🚀 #WomensHealth #HealthEquity #HereforHerHealth #healthequity https://lnkd.in/enJhv7Us

In April 2022, the Food and Drug Administration (FDA) released draft guidance to help medical product creators create a race and ethnicity diversity plan “to enroll adequate numbers of participants in clinical trials from underrepresented racial and ethnic populations in the United States.” The plan seeks to improve racial and ethnic diversity in clinical trial enrollment. In doing so, the FDA wants to support the U.S. government’s Cancer Moonshot plan to make cancer care more equitable. the FDA acknowledges that diversity is a broader question than race or ethnicity. The FDA recommends that clinical trial teams also track other diversity-related data points, including: Sex and gender identity. Age. Socioeconomic status. Disability. Pregnancy or lactation status. Comorbidity. Real world data shows, despite efforts to improve racial and ethnic diversity in clinical trial participation, many trials still run without a representative sample of participants from various racial and ethnic backgrounds. The FDA’s guidance seeks to help clinical researchers improve diversity in clinical trials without imposing additional mandates. #cgt #cellandgenetherapy #genetherapy #celltherapy #cdmo #2024trends #globaldata #asgct #viralvector #biotech

🚀 Exciting News! 🚀 I am thrilled to announce the publication of our latest research paper titled "Real-world evidence from Germany and the United States: Treatment initiation on low-efficacy versus high-efficacy therapies in patients with multiple sclerosis" in the journal Multiple Sclerosis and Related Disorders. 🔍 Key Findings: - Our study analyzes the adoption of the "hit-hard-and-early" (HHAE) strategy in multiple sclerosis (MS) treatment in Germany and the US from 2020 to 2022. - We found a significant increase in the adoption of HHAE strategy, with 29.6% of patients in Germany and 61.6% in the US starting with high-efficacy therapies. - High-efficacy therapy beginners were less likely to switch therapies compared to those starting with low-efficacy treatments. - These insights highlight a paradigm shift in MS management, emphasizing the benefits of starting with high-efficacy treatments to improve patient outcomes. This research based on our Permea Platform in collaboration with Komodo Health wouldn't have been possible without the incredible teamwork and dedication of my co-authors. A huge thank you to Dr. Steffeni Papukchieva HD (Hyung-Do) Kim Ann-Sophie Stratil Emily Magurne Apolline Jonckheere Maria Kahn Sebastian Schneeweiss Tjalf Ziemssen Your expertise and collaboration were invaluable in bringing this study to fruition. Looking forward to more groundbreaking research together! You can read the full paper here: https://lnkd.in/d6Xn7DCv #MultipleSclerosis #Research #Healthcare #HighEfficacyTherapies #TeamWork #ScientificPublication